Next-Generation Biologics Market Revenue to Attain USD 272.50 Bn by 2033

15 Jul 2025

Share :

Table of Content

1. Next-Generation Biologics Market Revenue and Trends 2025 to 2033 2. Market Overview 3. Segment Insights 4. Regional Insights 5. Next-Generation Biologics Market Coverage 6. Next-Generation Biologics Market Key Players

Next-Generation Biologics Market Revenue and Trends 2025 to 2033

The global next-generation biologics market revenue surpass USD 122.24 billion in 2025 and is predicted to attain around USD 272.50 billion by 2033, growing at a CAGR of 10.54%. The growth of the market is attributed to ongoing advancements in biotechnology, leading to the development of precision-engineered biologics, biosimilars, and bio-betters. The rising demand for personalized medicine and cell and gene therapies further support market growth.

Market Overview

The next-generation biologics market is experiencing rapid expansion due to several factors. The increasing prevalence of chronic diseases, including cancer, autoimmune disorders, and diabetes, is driving the demand for therapies that are both effective and highly targeted. Simultaneously, advancements in genetic engineering and recombinant DNA technologies are enabling the faster delivery of highly specific and effective biologics, such as antibody drug conjugates (ADCs), bispecific antibodies, and cell and gene therapies. Moreover, rising investment from major global biopharma companies, alongside robust regulatory support for innovation, has been reshaping the market landscape.

The rising demand for personalized medicine and biologics with enhanced efficacy, safety, and delivery is likely to spur future innovations, potentially leading to the replacement of traditional medicines or treatment approaches. Moreover, increasing focus on patient-centric care leads to the development of more effective and personalized medicines, opening up new growth avenues for the market.

Segment Insights

• By product type, the bispecific antibodies segment held the largest market share in 2024 due to their increased therapeutic potential. Their dual-targeting ability makes them suitable for treating a range of diseases simultaneously.
• By disease area, the oncology segment captured the largest share of the market in 2024, driven by the increased burden of cancer and heightened demand for novel targeted and personalized therapeutic options with improved clinical outcomes. Biologics have proven efficacy in treating various cancers, making them ideal for use in immunotherapies.
• By manufacturing platform, the mammalian cell culture segment sustained dominance in the market in 2024. This is primarily due to its ability to produce complex proteins at high yields, with excellent biocompatibility and scalability, while meeting stringent regulatory requirements.
• By route of administration, the intravenous (IV) segment led the market while holding a major share in 2024. This is primarily due to its potential for rapid, systemic delivery, precise dosing, and improved outcomes, thereby enhancing clinical efficacy. The increased demand for targeted drug delivery also bolstered the segment.
• By distribution channel, the hospital pharmacies segment dominated the market in 2024. This is primarily due to their well-established cold-chain infrastructure, which enables proper management of medications and access to immediate care.

Regional Insights

North America registered dominance in the next-generation biologics market, capturing the largest share in 2024. The U.S. is a significant contributor to regional market growth, thanks to the presence of some of the world's leading biopharmaceutical companies. A robust R&D ecosystem, rising regulatory approvals for cell and gene therapies, and increased healthcare expenditures are among the major factors that are bolstering market growth.

Asia Pacific is likely to experience the fastest growth in the market. This is primarily due to the increasing prevalence of chronic diseases, investments in life sciences R&D, and the demand for personalized therapies. The increasing government efforts to boost the production of cell and gene therapies and promote biotechnology innovations further drive the market's growth within the region.

Next-Generation Biologics Market Coverage

Recent Development

• In June 2025, WuXi Biologics, a leading CRDMO, launched the WuXiHigh™2.0, a high-throughput formulation development platform designed for high concentration biologics. The platform enables protein concentrations of up to 230mg/mL and achieves viscosity reduction by up to 90%. 
  (Source: https://www.wuxibiologics.com)

Next-Generation Biologics Market Key Players

• Roche Holding AG
• Amgen Inc.
• Johnson & Johnson (Janssen Biotech)
• Bristol-Myers Squibb (BMS)
• Pfizer Inc.
• Novartis AG
• Merck & Co., Inc.
• AbbVie Inc.
• Gilead Sciences, Inc.
• Sanofi S.A.
• AstraZeneca plc
• Takeda Pharmaceutical Co. Ltd.
• Regeneron Pharmaceuticals
• Biogen Inc.
• UCB S.A.
• Alnylam Pharmaceuticals
• Moderna, Inc.
• BioNTech SE
• Bluebird Bio
• Sangamo Therapeutics

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6397

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com |+1 804 441 9344